These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study. De Sousa-Amorim E; Del Peso G; Bajo MA; Alvarez L; Ossorio M; Gil F; Bellon T; Selgas R Perit Dial Int; 2014; 34(6):582-93. PubMed ID: 24584614 [TBL] [Abstract][Full Text] [Related]
30. Course of C-reactive protein during continuous peritoneal dialysis-associated peritonitis. Troidle L; Kliger A; Gorban-Brennan N; Finkelstein F Nephrology (Carlton); 2005 Oct; 10(5):442-5. PubMed ID: 16221092 [TBL] [Abstract][Full Text] [Related]
31. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis. Otsuka Y; Nakayama M; Ikeda M; Sherif AM; Yokoyama K; Yamamoto H; Kawaguchi Y Clin Exp Nephrol; 2005 Dec; 9(4):315-319. PubMed ID: 16362159 [TBL] [Abstract][Full Text] [Related]
32. Outcome and complications in peritoneal dialysis patients: a five-year single center experience. Alwakeel JS; Alsuwaida A; Askar A; Memon N; Usama S; Alghonaim M; Feraz NA; Shah IH; Wilson H Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):245-51. PubMed ID: 21422621 [TBL] [Abstract][Full Text] [Related]
33. Encapsulating peritoneal sclerosis: presentation without preceding symptoms. Yiannoullou P; Kanesalingam K; van Dellen D; Augustine T Saudi J Kidney Dis Transpl; 2015 Mar; 26(2):329-34. PubMed ID: 25758884 [TBL] [Abstract][Full Text] [Related]
34. Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients. Betjes MG; Habib SM; Boeschoten EW; Hemke AC; Struijk DG; Westerhuis R; Abrahams AC; Korte MR Perit Dial Int; 2017; 37(2):230-234. PubMed ID: 28360369 [TBL] [Abstract][Full Text] [Related]
35. mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures. Ghadimi M; Dashti-Khavidaki S; Khalili H Ren Fail; 2016 Nov; 38(10):1574-1580. PubMed ID: 27425661 [TBL] [Abstract][Full Text] [Related]
36. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Yamamoto R; Nakayama M; Hasegawa T; Miwako N; Yamamoto H; Yokoyami K; Ikeda M; Kato N; Hayakawa H; Takahashi H; Otsuka Y; Kawaguchi Y; Hosoya T Adv Perit Dial; 2002; 18():131-4. PubMed ID: 12402604 [TBL] [Abstract][Full Text] [Related]
38. Time Is Not Always the Matter: An Instance of Encapsulating Peritoneal Sclerosis Developing in a Patient on Peritoneal Dialysis for a Short Term. De Oleo RR; Villanueva H; Lwin L; Katikaneni M; Yoo J Adv Perit Dial; 2016; 32():19-21. PubMed ID: 28988585 [TBL] [Abstract][Full Text] [Related]
39. Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis. Huddam B; Azak A; Koçak G; Başaran M; Voyvoda N; Duranay M Ren Fail; 2012; 34(3):387-9. PubMed ID: 22263915 [TBL] [Abstract][Full Text] [Related]
40. Seventeen years' experience of surgical options for encapsulating peritoneal sclerosis. Kawanishi H; Shintaku S; Moriishi M; Dohi K; Tsuchiya S Adv Perit Dial; 2011; 27():53-8. PubMed ID: 22073830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]